UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________ FORM 10-K _________________________ (I.R.S. Employer Identification No.) Title of each class Trading Symbol(s) Name of each exchange on which registered Class A Common Stock of Evolent Health, Inc., par value $0.01 per shareEVH New York Stock Exchange (Mark One) S ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPO ...

Evolent Health, Inc. (NYSE:EVH) Q3 2020 Earnings Conference Call November 5, 2020 5:00 PM ET Company Participants Seth Blackley - Chief Executive Officer John Johnson - Chief Financial Officer Conference Call Participants Ryan Daniels - William Blair Robert Jones - Goldman Sachs Matthew Gilmore - Baird Jessica Tassan - Piper Sandler Charles Rhyee - Cowen Sandy Draper - Truist Operator Welcome to Evolent Health's Earnings Conference Call for the Quarter Ended September 30, 2020. As a reminder, this conferen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________ FORM 10-Q _________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37415 | --- | --- | --- | --- | --- | --- | --- | --- | |-------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________ FORM 10-Q _________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37415 _________________________ Evolent Health, Inc. | --- | --- | --- | --- ...

Evolent Health, Inc. (NYSE:EVH) Q2 2020 Earnings Conference Call August 4, 2020 5:00 PM ET Company Participants Frank Williams - Co-Founder & CEO John Johnson - CFO Seth Blackley - Co-Founder, President Conference Call Participants Ryan Daniels - William Blair Jack Rogoff - Goldman Sachs Matthew Gilmore - Baird Charles Rhyee - Cowen Richard Close - Canaccord Genuity Sandy Draper - SunTrust Anne Samuel - JPMorgan Operator Welcome to Evolent Health Earnings Conference Call for the Quarter Ended June 30, 2020. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________ FORM 10-Q _________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37415 _________________________ Evolent Health, Inc. | --- | --- | --- | -- ...

| --- | --- | |----------------------------------------------------------------------|-------| | | | | | | | Bank of America Health Care Conference: Evolent Health May 13, 2020 | | | | | | | | Safe Harbor Statement Certain statements in this presentation and in other written or oral statements made by us or on our behalf are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). A forward-looking statement is a statement that is not a historical fa ...

Evolent Health, Inc. (NYSE:EVH) Q1 2020 Results Earnings Conference Call May 7, 2020 5:00 PM ET Company Participants Frank Williams - Co-Founder, Chief Executive Officer John Johnson - Chief Financial Officer Seth Blackley - Co-Founder, President Conference Call Participants Charles Rhyee - Cowen Robert Jones - Goldman Sachs Ryan Daniels - William Blair Sandy Draper - SunTrust Jessica Tassan - Piper Sandler Operator Welcome to Evolent Health earnings conference call for the quarter ended March 31, 2020. As ...

| --- | --- | |-------------------------------------------------------------|-------| | | | | | | | Cowen Health Care Conference: Evolent Health March 3, 2020 | | | | | Safe Harbor Statement Certain statements in this presentation and in other written or oral statements made by us or on our behalf are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). A forward-looking statement is a statement that is not a historical fact and, without limitati ...

Revenue Growth - Evolent Health reported a revenue increase of 25% year-over-year, reaching $500 million for the fiscal year[8] - Evolent Health, Inc. reported a revenue of $125 million for the fiscal year, reflecting a year-over-year increase of 20%[8] - Evolent Health anticipates a revenue guidance of $150 million to $160 million for the next fiscal year, indicating a projected growth rate of 20-28%[8] - Evolent Health expects to maintain a revenue growth rate of 20-25% for the next fiscal year[12] Membership Growth - The company achieved a total membership growth of 30%, bringing the total to 1.5 million members[8] - The company has expanded its user base to 1.5 million members, representing a growth of 15% compared to the previous year[8] Acquisitions - The company completed the acquisition of Valence Health, which is expected to contribute an additional $100 million in annual revenue[12] - The company has completed the acquisition of Valence Health, which is expected to contribute approximately $30 million in annual revenue[8] Financial Performance - Evolent Health's operating margin improved to 15%, up from 10% in the previous year[8] - The company reported a net income of $20 million, compared to a net loss of $5 million in the prior year[8] - The company reported a net loss of $10 million for the year, which is an improvement from a net loss of $15 million in the previous year[8] - Evolent Health's cash flow from operations increased by 40%, totaling $80 million for the year[8] - Evolent Health's cash and cash equivalents stood at $50 million, providing a solid liquidity position for future investments[8] Investment and Development - The company is investing $50 million in new technology development to enhance its healthcare management platform[12] - The company is committed to maintaining a strong balance sheet while investing in technology and infrastructure to support growth initiatives[8] - Evolent Health is focusing on new product development, particularly in value-based care solutions, which are expected to enhance service offerings and market competitiveness[8] Market Expansion - Evolent Health plans to expand its market presence by entering three new states in the upcoming year[12] - Evolent Health is actively pursuing market expansion strategies, including partnerships with new healthcare providers and entry into additional states[8] Product Launches - The company anticipates launching two new products aimed at value-based care in the next quarter[12] Revenue Model - Evolent Health's performance-based contracts are projected to account for 60% of total revenue, highlighting a shift towards risk-sharing arrangements[8]